Here's Why You Should Retain OPK Stock in Your Portfolio for Now

OPKO Health, Inc. OPK is well-positioned for growth in the coming quarters, supported by the potential of RAYALDEE. Optimism surrounding the stock is driven by RAYALDEE’s strong performance, strategic partnerships, BioReference restructuring and multiple pipeline catalysts. However, overdependence on RAYALDEE, early-stage clinical development risks and exposure to competitive, macroeconomic and currency pressures remain key concerns.

Shares of this Zacks Rank #3 (Hold) company have gained 17.4% in the year-to-date period, outperforming the industry's 6.4% decline and the S&P 500’s 11.7% rise.

This renowned multinational biopharmaceutical and diagnostics company has a market capitalization of $1.10 billion. OPK predicts 23.3% bottom-line growth for 2026 and anticipates maintaining its performance going forward. The company’s earnings surpassed estimates in three of the trailing four quarters and met in one, the average surprise being 95.09%.

Image Source: Zacks Investment Research

Factors Favoring OPK Stock

Diversified Pharmaceutical Portfolio and Strategic Partnerships: OPKO Health is broadening its pharmaceutical operations beyond Rayaldee through NGENLA, international pharmaceutical activities and strategic partnerships. NGENLA, commercialized by Pfizer, is approved in more than 50 markets and continues to benefit from the shift toward once-weekly growth hormone therapy, while additional label-expansion studies could further increase its market opportunity.

The amended Nicoya agreement expands Rayaldee’s potential in Greater China, with OPK receiving a 15% equity interest and remaining eligible for up to $115 million in development, regulatory and sales-based milestones. Collaborations with Regeneron, Merck and BARDA enable OPK to advance multiple programs while limiting its own development spending. These partnerships provide potential access to milestone payments and future royalties while supporting the company’s broader pharmaceutical growth strategy.

BioReference Restructuring and Operational Efficiency: OPKO Health is continuing to reposition BioReference as a more focused regional diagnostics business following the sale of select oncology assets to Labcorp. The retained operations are centered on clinical testing in New York and New Jersey, correctional healthcare and the proprietary 4Kscore prostate cancer test. Management has significantly reduced the workforce and is consolidating or relocating patient service centers, outsourcing selected lower-value esoteric testing and increasing the use of laboratory capacity for clinical trials and sample-based work.

These measures are designed to improve efficiency and streamline the cost structure. The 4Kscore remains a key long-term opportunity, particularly if Medicare coverage requirements are broadened to support greater adoption in primary care. Management continues to evaluate this opportunity while awaiting further clarity from CMS.

Advancing Clinical Pipeline Across Multiple Therapeutic Areas: OPKO Health is progressing a diverse pipeline spanning oncology, immunology, infectious diseases, metabolic disorders and endocrine conditions. ModeX has five programs in clinical development, including MDX2001, MDX2003 and MDX2004, while MDX2301 is advancing with BARDA funding and MDX2201 has completed Phase I under Merck funding. The company expects additional clinical milestones through late 2026 and 2027.

Beyond ModeX, OPK is advancing MDX3001, an in vivo CAR-T candidate targeting autoimmune diseases, toward first-in-human testing, while OPK-88006, a once-weekly dual GLP-1/glucagon agonist, is being evaluated in MASH. OPK8801001 is advancing as a potential once-weekly treatment for acromegaly, and the oral PTH program with Entera is moving toward an IND filing. These programs expand OPK’s exposure to large therapeutic markets and provide multiple potential catalysts for future growth.

Factors That May Offset OPK's Gains

Clinical Development and Competitive Risks: OPKO Health’s long-term growth prospects depend heavily on a broad pipeline that remains at relatively early stages of development. MDX2001, MDX2003, MDX2004 and MDX2301 are in Phase I testing, while MDX3001 has yet to enter human trials and OPK-88006 is still being evaluated in early-stage studies. Favorable preclinical findings or initial biological activity may not translate into later-stage efficacy or regulatory approval.

The company’s novel multispecific antibody and in vivo CAR-T technologies introduce additional development complexity. OPKO competes with larger pharmaceutical and diagnostics companies that have greater financial resources, commercial infrastructure and payer leverage. Pipeline candidates must demonstrate differentiation in efficacy, safety, convenience or durability to achieve commercial success. Competition for MASH trial participants could also affect recruitment and development timelines.

BioReference Execution and Continued Losses: OPKO Health continues to restructure BioReference following recent asset divestitures, creating an opportunity for a more focused and efficient diagnostics business but also increasing execution risk. Workforce reductions, patient service center consolidation and outsourcing initiatives must be implemented without materially affecting testing volumes or customer service. The 4Kscore remains an important growth opportunity, although broader primary-care adoption depends partly on potential changes in Medicare reimbursement policy.

OPK remains loss-making as it funds multiple clinical programs and maintains its commercial and diagnostic operations. Although partnership revenues and external funding, including support from BARDA and collaborations with Pfizer, Merck and Regeneron, provide additional resources, these sources are partly dependent on clinical, regulatory and commercial outcomes. Delays, higher R&D spending or slower BioReference improvement could prolong the path to sustainable profitability.

Macroeconomic, Geographic and Currency Exposure: OPKO Health’s international operations expose the company to geopolitical, regulatory, reimbursement and foreign exchange risks. Its businesses and development activities in Israel, Europe and Latin America can be affected by regional instability, logistics disruptions and changing healthcare policies. Reimbursement pressure from payers may affect diagnostics utilization and the company’s ability to expand certain services.

Currency movements represent an additional source of volatility, with approximately 33.3% of revenues in the first six months of 2026 denominated in currencies other than the U.S. dollar, primarily the Chilean peso and euro. OPK uses foreign exchange forward contracts mainly to manage Chilean peso exposure, but these measures cannot eliminate all currency risk. Continued adverse exchange-rate movements could therefore affect reported revenues, asset values and period-to-period financial comparisons.

OPKO Health, Inc. Price

OPKO Health, Inc. price | OPKO Health, Inc. Quote

Estimate Trends of OPK

OPKO Health is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its loss per share has contracted by 6 cents to 23 cents.

The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues and loss per share is pegged at $131.2 million and 6 cents, respectively. The estimate for revenues indicates a 10.2% fall from the year-ago quarter’s reported number, while that for loss implies a 300% decline.

Stocks to Consider

Some better-ranked stocks from the broader medical space are Globus Medical GMED, Veracyte VCYT and West Pharmaceutical WST.

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research